First clinical experience of the use of ustekinumab (Stelara) for treatment of psoriatic patients in Russia
The authors examined the efficacy and safety of treatment of patients suffering from moderate to severe forms of psoriasis with ustekinumab (blocker of р40 subunit of interleukin-12 and interleukin-23) taking into account the PASi index. They revealed high clinical efficacy of ustekinumab for treatment of psoriatic patients.